Table 3.
Univariate and multivariate analyses by patient and treatment characteristics
| Factors | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age, years | ||||
| ≥50 | 0.72 (0.28–1.84) | 0.493 | - | – |
| <50 | 1 | - | ||
| T stage | ||||
| T 3 | 2.18 (0.50–9.50) | 0.300 | - | – |
| T1–2 | 1 | - | ||
| Grade | ||||
| 3 | 1.65 (0.64–4.28) | 0.300 | - | – |
| 1–2 | 1 | - | ||
| Hormone receptor | ||||
| Negative | - | 0.083 | - | – |
| Positive | 1 | - | ||
| FNA | ||||
| Positive | 1.63 (0.64–4.15) 1 | 0.308 | - | – |
| Other | 1 | - | ||
| SLNB | ||||
| Positive | 1.10 (0.25–4.82) 1 | 0.899 | - | – |
| Other | 1 | - | ||
| Surgery | ||||
| BCT | 1.06 (0.40–2.85) | 0.902 | - | – |
| Mastectomy | 1 | - | ||
| Radiotherapy | ||||
| Yes | 0.55 (0.19–1.54) | 0.253 | - | – |
| No | 1 | - | ||
| ALND | ||||
| Yes | 2.05 (0.72–5.80) | 0.176 | - | – |
| No | 1 | - | ||
| Anthracycline + taxane | ||||
| Yes | 0.77 (0.30–1.93) | 0.572 | - | – |
| No | 1 | - | ||
| Residual DCIS | ||||
| Yes | 1.81 (0.70–4.70) | 0.221 | - | – |
| No | 1 | - | ||
| Endocrine therapy | ||||
| Yes | 0.09 (0.01–0.66) | 0.087 | 0.09 (0.01–0.66) | 0.018 |
| No | 1 | 1 | ||
| Adjuvant chemotherapy | ||||
| Yes | 1.05 (0.40–2.72) | 0.928 | - | – |
| No | 1 | - | ||
| Trastuzumab | ||||
| Yes | 0.31 (0.11–0.88) | 0.028 | 0.31 (0.11–0.89) | 0.030 |
| No | 1 | 1 | ||
HR, Hazard ratio; CI, confidence interval; FNA, fine needle aspirate; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; DCIS, ductal carcinoma in situ; BCT, breast-conserving therapy.